News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
BioCardia has recently completed the submission of CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval for the indication of ischemic heart failure (HF) with reduced ejection fraction.
EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, has announced the final closing of a Series A financing.
Nanjing Iaso Biotherapeutics and Innovent Biologics have received China National Medical Product Administration (NMPA) approval for Fucaso (equecabtagene autoleucel) as a treatment for patients with relapsed or refractory multiple myeloma who have...